Evidence map›Paper›PMID 25886386›Full record

ArticleBMC nephrology2015

Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.

Zeng Si Wang, Fei Xiong, Xiao Hang Xie, Dan Chen, Jian Hua Pan, Li Cheng

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 4 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Are the Therapeutic Effects of Huangqi (Journal of immunology research · 2017
    Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Observational
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zeng Si WangDepartment of Nephrology, Wuhan No.1 Hospital, Wuhan, 430000, Hubei Province, PR China. wangzengsi@hotmail.com.
Fei XiongDepartment of Nephrology, Wuhan No.1 Hospital, Wuhan, 430000, Hubei Province, PR China. xiongf23@sina.com.
Xiao Hang XieDepartment of Nephrology, Wuhan No.1 Hospital, Wuhan, 430000, Hubei Province, PR China. popethrone@sina.com.
Dan ChenDepartment of Nephrology, Wuhan No.1 Hospital, Wuhan, 430000, Hubei Province, PR China. chendan-429@163.com.
Jian Hua PanDepartment of Nephrology, Wuhan No.1 Hospital, Wuhan, 430000, Hubei Province, PR China. panjianhua_hust@126.com.
Li ChengDepartment of Nephrology, Wuhan No.1 Hospital, Wuhan, 430000, Hubei Province, PR China. chenglimg07@126.com.
Wuhan No.1 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetic nephropathy (DN) is a major cause of Chronic Kidney Disease and End-Stage Renal Disease throughout the world; however, the reversibility of diabetic nephropathy remains controversial. Endoplasmic reticulum (ER) stress plays an important role in the pathogenesis of DN. Astragaloside IV (AS-IV) is derived from Astragalus membranaceus (Fisch) Bge, a widely used traditional herbal medicine in China, and has diverse pharmacological activities including the attenuation of podocyte injury and amelioration of proteinuria in idiopathic nephrotic syndrome. The present study aimed to investigate the effect and mechanism of AS-IV on proteinuria in the rat streptozotocin (STZ)-induced model of diabetes.

methodsMale Sprague-Dawley (SD) rats were randomly divided into four groups: normal control (Normal group), diabetic nephropathy (Model group), diabetic nephropathy plus AS-IV treatment (AS-IV group) and diabetic nephropathy plus 4-phenyl butyric acid treatment (PBA group). ER stress was induced in cultured human podocytes, pretreated with or without AS-IV, with tunicamycin (TM). At the end of 8 weeks, serum creatinine (Scr), blood urea nitrogen (BUN) and 24-hour urinary protein excretion rate (UAER) were determined. Renal morphology was examined after periodic acid-Schiff staining of kidney sections. Apoptosis of podocytes was measured by flow cytometry. The total expression and phosphorylation of eIF2α, PERK and JNK, and the expression of CHOP and cleaved caspase-3 were determined by western blotting. The expression of glucose-regulated protein 78 (GRP78) and 150 kDa oxygen-regulated protein (ORP150) mRNA and protein was determined by real-time PCR and western blotting respectively.

resultsAS-IV treatment significantly reduced urinary albumin excretion, plasma creatinine and blood urea nitrogen levels, and prevented the mesangial matrix expansion and increase in mean mesangial induced by STZ. AS-IV also prevented the phosphorylation of eIF2α, PERK and JNK, and inhibited the expression of GRP78 and ORP150 markedly, both in vivo and in vitro. AS-IV inhibited the TM-induced apoptosis of podocytes, concomitant with decreased CHOP expression and cleaved caspase-3.

conclusionsThis study supports the hypothesis that AS-IV reduces proteinuria and attenuates diabetes, which is associated with decreased ER stress. This might be an important mechanism in the renoprotective function of AS-IV in the pathogenesis of DN.

Indexed as

Analysis of VarianceAnimalsApoptosisBlotting, WesternCells, CulturedDiabetes Mellitus, ExperimentalDiabetic NephropathiesDisease Models, AnimalEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressMalePodocytesProteinuriaRandom AllocationRatsRats, Sprague-Dawleyastragaloside AEndoplasmic Reticulum Chaperone BiPHSPA5 protein, humanSaponinsStreptozocinTriterpenes

Identifiers

PMID25886386
PMCPMC4387678
OpenAlexW2029686598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.